Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation

Background: Non-adherence to antipsychotics in schizophrenia is associated with an increased risk of psychotic relapse and hospitalization, a risk that is reduced with the use of long-acting injectable (LAI) antipsychotics. Randomized clinical trials (RCTs) have demonstrated the efficacy of paliperi...

Full description

Bibliographic Details
Main Authors: Olivier Corbeil, Anne-Marie Essiambre, Laurent Béchard, Audrey-Anne Roy, Maxime Huot-Lavoie, Sébastien Brodeur, Ranjith Chandrasena, Chantale Thériault, Candice Crocker, Jean-Pierre Melun, Phil Tibbo, Marie-France Demers, Marc-André Roy
Format: Article
Language:English
Published: SAGE Publishing 2022-11-01
Series:Therapeutic Advances in Psychopharmacology
Online Access:https://doi.org/10.1177/20451253221136021

Internet

https://doi.org/10.1177/20451253221136021

Similar Items